Drug Information



Brand Name:Trisenox Trade Name:arsenic trioxide
FDA Approved For:Second line treatment of relapsed or refractory APL following ATRA plus an anthracycline. Pediatric Use:Safety and effectiveness in pediatric patients below the age of 5 years have not been studied.
Carcinogen:Carcinogenesis: Carcinogenicity studies have not been conducted with TRISENOX™ by intravenous administration. The active ingredient of TRISENOX™, arsenic trioxide, is a human carcinogen.Mutagen:Arsenic trioxide and trivalent arsenite salts have not been demonstrated to be mutagenic to bacteria, yeast or mammalian cells. Arsenite salts are clastogenic in vitro (human fibroblasts, human lymphocytes, Chinese hamster ovary cells, Chinese hamster V79 lung cells). Trivalent arsenic produced an increase in the incidence of chromosome aberrations and micronuclei in bone marrow cells of mice. The effect of arsenic on fertility has not been adequately studied.
Manufacturer and/or Distributor:Cell Therapeutic

Adverse Reactions:

For a complete list of adverse reactions please click on the link "More Information" for this drug.)

More Information